Estados Unidos · Plataformas y datos · MarketBeat

HLS Therapeutics Targets 2027 Growth With Cardiovascular Expansion and New Deals

Publicado por MarketBeat · Estados Unidos hace 1 h

HLS Therapeutics (TSE:HLS) outlined plans to build on its cardiovascular portfolio and pursue additional business-development opportunities as the specialty pharmaceutical company…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

HLS Therapeutics Targets 2027 Growth With Cardiovascular Expansion and New Deals

También te puede interesar

Australia's Q3 PPI rises 1.1% Q/Q; annual producer inflation holds steady at 3.6%

These 2 Nearly 100% Historically Accurate Market Signals Are Conflicting. Here's What Investors Should Do.

BYD shares dip as Q3 earnings disappoint

What gave this city its ‘best place to retire’ crown? You can actually afford to live there.

Sify (SIFY) Q2 2027 Earnings Call Transcript

Vigonvita Investors Extend Share Lock‑Up to Signal Long‑Term Confidence

HLS Therapeutics Targets 2027 Growth With Cardiovascular Expansion and New Deals

Compartir

También te puede interesar

Australia's Q3 PPI rises 1.1% Q/Q; annual producer inflation holds steady at 3.6%

These 2 Nearly 100% Historically Accurate Market Signals Are Conflicting. Here's What Investors Should Do.

BYD shares dip as Q3 earnings disappoint

What gave this city its ‘best place to retire’ crown? You can actually afford to live there.

Sify (SIFY) Q2 2027 Earnings Call Transcript

Vigonvita Investors Extend Share Lock‑Up to Signal Long‑Term Confidence